Replay available

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2023 Earnings Call

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) Q2 2023 earnings conference call, held 2023-08-01. Replay captured from the company's public earnings webcast.

Tue, August 1, 2023 at 4:30 PMendedReplay
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2023 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Ray Fury

Executive Vice President, General Counsel, and Corporate Secretary

Raul Rodriguez-Raul

President and Chief Executive Officer

Dave Santos

Chief Commercial Officer

Dean Shorno

Chief Financial Officer

Igal Nishomovitz

Analyst, Citi

Kristin Kluska

Analyst, Cantor Fitzgerald

Joe Penn Guinness

Analyst, H.C. Wainwright

Yun Yang

Analyst, Jefferies

Allison Brathel

Analyst, Piper Sandler

Kalpit Patel

Analyst, B. Riley Securities

Replay transcript excerpt

Greetings and welcome to the Rigel Pharmaceuticals Financial Conference Call for the second quarter of 2023. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce our first speaker, Ray Fury, Rigel's Executive Vice President, General Counsel, and Corporate Secretary. Thank you, Mr. Fury. You may begin. Welcome to our second quarter 2023 financial results and business update conference call. The financial press release for the second quarter 2023 was issued a short while ago and can be viewed along with the slides for this presentation in the news and events section of our investor relations site on Rigel.com. As a reminder, during today's call, we may make forward looking statements regarding our financial outlook and our plans and timing for regulatory and product development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent annual report on Form 10-K for the year ended December 31st, 2022, and the subsequent filings with the SEC including our second quarter quarterly report on Form 10Q on file with the SEC. Any forward-looking statements are made only as of today's date, and we undertake no obligation to update these forward-looking statements to reflect subsequent events or circumstances. At this time, I would like to turn the call over to Raul, to our President and Chief Executive Raul Rodriguez-Raul. Thank you, Ray, and thank you everyone for joining today. Al...

More from Rigel Pharmaceuticals, Inc.